Compare FMC & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FMC | ANIP |
|---|---|---|
| Founded | 1910 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | N/A | N/A |
| Metric | FMC | ANIP |
|---|---|---|
| Price | $16.24 | $79.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 6 |
| Target Price | $23.85 | ★ $107.33 |
| AVG Volume (30 Days) | ★ 3.8M | 549.9K |
| Earning Date | 02-04-2026 | 02-27-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.67 |
| Revenue | ★ $3,608,400,000.00 | $826,880,000.00 |
| Revenue This Year | N/A | $44.35 |
| Revenue Next Year | $1.01 | $11.13 |
| P/E Ratio | ★ N/A | $47.69 |
| Revenue Growth | N/A | ★ 48.87 |
| 52 Week Low | $12.17 | $54.10 |
| 52 Week High | $55.27 | $99.50 |
| Indicator | FMC | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 63.14 | 42.99 |
| Support Level | $15.14 | $78.10 |
| Resistance Level | $16.40 | $81.99 |
| Average True Range (ATR) | 0.66 | 2.58 |
| MACD | 0.01 | -0.38 |
| Stochastic Oscillator | 69.63 | 15.16 |
FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.